Parallel Advisors’s Inhibikase Therapeutics IKT Stock Holding History
Bought
Maintained
Sold
Other funds holding IKT
SL
Parallel Advisors's IKT Position: Q3 2026 in Review
Parallel Advisors opened a new position in Inhibikase Therapeutics (IKT) in Q3 2026: 3,217 shares worth $6.61K. The stake represents ﹤0.01% of the portfolio and ranks #3251 among its holdings.
110 funds tracked by Wall St. Rank hold IKT as of Q3 2026.
- Parallel Advisors held 3,217 shares of Inhibikase Therapeutics worth $6.61K as of Q3 2026.
- Inhibikase Therapeutics was a new Parallel Advisors position in Q3 2026.
- Inhibikase Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q3 2026, its #3251 holding.
- 110 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q3 2026.
Based on Parallel Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.